東瑞製藥(02348.HK):中山康方擬購買東瑞生物於康融東方的35%股權
格隆匯2月9日丨東瑞製藥(02348.HK)發佈公吿,2024年2月8日,東瑞生物(為公司的全資附屬公司)與中山康方(康方生物的全資附屬公司)、康方生物及康融東方訂立該協議,據此,東瑞生物同意出售及中山康方同意購買東瑞生物於康融東方的35%股權,購買價約為人民幣2.67億元。該協議亦要求康融東方償還該等貸款及截至2024年2月8日的應計利息。因此,東瑞生物根據該協議有權收取合共人民幣3.9億元。
康融東方主要從事開發(a)伊努西單抗注射液(抗PCSK9單克隆抗體(AK102)),用於治療兩類適應症(即(i)原發性高膽固醇血癥和混合型高脂血症,及(ii)雜合子型家族性高膽固醇血癥),該藥物已完成三期臨牀試驗及新藥上市許可申請已於2023年6月獲國家藥品監督管理局受理;及(b)普絡西單抗(VEGFR-2單克隆抗體(AK109)),擬用於治療晚期實體腫瘤,於本公吿日期,該藥物正在進行二期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.